NCT03868423 Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers Status WITHDRAWN Phase PHASE2
NCT03737994 Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Status TERMINATED Phase PHASE2
NCT03719898 Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma Status WITHDRAWN Phase PHASE2
NCT03707938 Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03596866 A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer Status COMPLETED Phase PHASE3
NCT03546894 A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors Status COMPLETED Phase N/A
NCT03535740 A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib Status COMPLETED Phase PHASE2
NCT03420742 A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors Status COMPLETED Phase PHASE1
NCT03410108 Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Status COMPLETED Phase PHASE2
NCT02784158 An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer Status NO_LONGER_AVAILABLE Phase N/A
NCT02737501 ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants Status COMPLETED Phase PHASE3
NCT02706626 Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors Status TERMINATED Phase PHASE2
NCT02094573 A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib Status COMPLETED Phase PHASE2
NCT01449461 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) Status COMPLETED Phase PHASE1/PHASE2